RedHill Wins Two More U.S. Patents on Gastrointestinal Therapy BEKINDA

RedHill Wins Two More U.S. Patents on Gastrointestinal Therapy BEKINDA
RedHill Biopharma has received two more U.S. patents for its gastrointestinal therapy BEKINDA (ondansetron). The patents cover RedHill's propriety formulation of its extended-release ondansetron tablet, and the way BEKINDA is used in treatment. "We are very pleased with the allowance of two additional U.S. patents for BEKINDA," Danielle Abramson, RedHill's director of intellectual property and research, said in a press release. "This is an important addition to RedHill's strong IP [intellectual property] portfolio that will further enhance our protection of BEKINDA. "We are approaching significant milestones with BEKINDA in the coming months," Abramson added. She was referring to the results of two ongoing clinical trials that are expected in the second and third quarters of 2017. BEKINDA is an anti-emetic drug, or one that treats nausea and vomiting. It targets multiple gastrointestinal problems, including irritable bowel syndrome (IBS), acute gastroenteritis and gastritis. Patients take the tablet once a day. The randomized, double-blind, pl
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *